• Result of AGM

    Source: Nasdaq GlobeNewswire / 29 Oct 2021 12:40:00   America/New_York

    GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that at its Annual General Meeting held on 29th October 2021, all resolutions were duly passed, with the exception of Proposal 2, relating to the approval of the 2021 Equity Incentive Plan.

    About MaxCyte

    MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

    MaxCyte Contacts:

    US IR Adviser
    Gilmartin Group
    David Deuchler, CFA

    +1 415-937-5400
     ir@maxcyte.com
      
    US Media Relations
    Laura Morgan
    Sam Brown Healthcare Communications

    +1 951-333-9110
    lauramorgan@sambrown.com
      
    Nominated Adviser and Joint Corporate Broker
    Panmure Gordon
    Emma Earl / Freddy Crossley
    Corporate Broking
    Rupert Dearden

    +44 (0)20 7886 2500
      
    UK IR Adviser
    Consilium Strategic Communications
    Mary-Jane Elliott
    Chris Welsh

    +44 (0)203 709 5700
    maxcyte@consilium-comms.com


    Primary Logo

Share on,